Gisela Gonzalez
Business Development Manager at CIMAB SA
Articles
Manufacturing Process Development for an Epidermal Growth Factor-Based Cancer Vaccine
Beatriz Garcia;Aurora Tamara Garcia;Gryssell Rodriguez;Tania Crombet;Alejandro Portillo;Ariadna Cuevas;Lisel Viña;Gisela Gonzalez;Ernesto Chico;Loany Calvo;Airama Albisa
October 2nd 2008The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapy targeting the epidermal growth factor (EGF). The vaccine is composed of a chemical conjugate of EGF and a carrier protein (rP64k), designed to trigger an anti-EGF antibody response. The results of studies of molecular characterization, immunogenic activity, and clinical data are presented here.
Latest Updated Articles
Published: October 11th 2024 | Updated: March 3rd 2025
Exploring New Advancements in ADC Technologies (CPHI Milan 2024)
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: April 3rd 2025 | Updated: April 24th 2025
GROUNDBREAKING ACHIEVEMENTS: 3CON's Revolutionary RNase Inactivation Method and Outstanding, Highly Efficient Single-Use Bag Production Solutions.
Published: April 1st 2025 | Updated: April 24th 2025
Facing the Latest Patent Cliff
Published: April 5th 2025 | Updated: April 24th 2025
Overcoming Biosimilar Scaling Challenges
